Bausch & Lomb CorpBLCO
What Bausch & Lomb Corp does.
Bausch + Lomb Corporation (and its subsidiaries) (“Bausch + Lomb,” “we,” “us,” “our” or the “Company”) is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Founded in 1853, Bausch + Lomb has a significant global research, development, manufacturing and commercial footprint of approximately 13,000 employees and a presence in approximately 100 countries. As a fully integrated eye health business, Bausch + Lomb has a comprehensive portfolio of approximately 400 products, which includes an established line of contact lenses, intraocular lenses ("IOLs") and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market.
Bausch + Lomb is a subsidiary of Bausch Health Companies Inc. (“BHC”), with BHC directly or indirectly holding 310,449,643 Bausch + Lomb common shares, which represents approximately 88% of the issued and outstanding common shares of Bausch + Lomb, as of February 11, 2026. On August 6, 2020, BHC announced its plan to separate our eye health business into an independent publicly traded entity, separate from the remainder of BHC (the “Separation”). This resulted in the initial public offering of Bausch + Lomb (the “B+L IPO”), and our common shares began trading on the New York Stock Exchange (“NYSE”) and the Toronto Stock Exchange (“TSX”), in each case under the ticker symbol “BLCO”, on May 6, 2022. Prior to the completion of the B+L IPO, we were an indirect wholly-owned subsidiary of BHC. See Note 2, “SIGNIFICANT ACCOUNTING POLICIES” to our audited Consolidated Financial Statements for additional information.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.8B | $3.8B | $4.1B | $4.8B | $5.1B |
| Net income | -$18.0M | $182.0M | $6.0M | -$260.0M | -$317.0M | -$360.0M |
| Free cash flow | $269.0M | $680.0M | $170.0M | -$198.0M | -$59.0M | -$66.0M |
More on BLCO.
- Bausch & Lomb Corp summary
- Bausch & Lomb Corp financial statements
- Bausch & Lomb Corp key metrics
- Bausch & Lomb Corp health scores and style box
- Bausch & Lomb Corp earnings
- Bausch & Lomb Corp dividends
- Bausch & Lomb Corp valuation
- Bausch & Lomb Corp ownership and insiders
- Bausch & Lomb Corp peers
Figures from Bausch & Lomb Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.